{"corpus_id":24762552,"paper_sha":"5d0cc1a48bc9e7fb46ba1db64448d4ff4924b388","doi":"10.2188/jea.16.201","arxiv_id":null,"pmid":16951539,"pmcid":"7683703","mag_id":2073425770,"dblp_id":null,"acl_id":null,"title":"Pravastatin Use and the Five-year Incidence of Cancer in Coronary Heart Disease Patients: from the Prevention of Coronary Sclerosis Study","year":2006,"publication_date":"2006-09-01","venue":"Journal of Epidemiology","journal":{"name":"Journal of Epidemiology","pages":"201 - 206","volume":"16"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Randomized Controlled Trial"],"s2_fields_of_study":["Medicine"],"reference_count":43,"citation_count":47,"influential_citation_count":5,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Anticholesteremic Agents","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000924"},{"d":"Cholesterol","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D002784"},{"d":"Coronary Disease","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D003327"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D019161"},{"d":"Incidence","mj":false,"ui":"D015994"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Neoplasms","mj":false,"qs":[{"q":"chemically induced","mj":true,"ui":"Q000139"},{"q":"epidemiology","mj":false,"ui":"Q000453"}],"ui":"D009369"},{"d":"Pravastatin","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D017035"},{"d":"Proportional Hazards Models","mj":false,"ui":"D016016"},{"d":"Risk","mj":false,"ui":"D012306"},{"d":"Smoking","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D012907"}],"chemicals":[{"n":"Anticholesteremic Agents","ui":"D000924","reg":"0"},{"n":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","ui":"D019161","reg":"0"},{"n":"Cholesterol","ui":"D002784","reg":"97C5T2UQ7J"},{"n":"Pravastatin","ui":"D017035","reg":"KXO2KT9N0G"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.jstage.jst.go.jp/article/jea/16/5/16_5_201/_pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/5d0cc1a48bc9e7fb46ba1db64448d4ff4924b388","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND Although the short-term safety of statins is well established, their potential carcinogenicity in the long term is still being debated. The aim of this study was to investigate the association between statin-therapy and the incidence of cancer in coronary heart disease patients. METHODS The subjects were 263 patients with coronary heart disease who were from Osaka prefecture and who were admitted to the Osaka Medical Center for Cancer and Cardiovascular Diseases between September 28, 1991 and March 31, 1995. The five-year cancer incidence among the subjects was checked using the database of the institution-based cancer registry of the hospital as well as the population-based Osaka Cancer Registry. The Cox’s proportional hazards ratios (HRs) of all cancer incidence and observed/expected (O/E) ratios by cancer site were calculated. RESULTS Cancer incidence was observed in 17 patients during the follow-up period. Age (HR=1.16 per one year of age) and continuous smoking during the period (HR=5.82 compared to not smoking during the period) were significantly associated with cancer incidence using multivariable analysis. After being adjusted for sex, age, total serum cholesterol level and smoking habit, the HR of cancer incidence with pravastatin use was 0.78 (95% confidence interval: 0.18-3.46). In the O/E analysis, significantly elevated risks were found for bladder cancer in all the subjects (HR=8.93), as well as in the pravastatin use patients (HR=13.76). CONCLUSIONS Pravastatin use for 5 years did not indicate an increase in over all cancer risk.","claims":[{"public_id":"cl_c0cbba752a00713606631f7c27497675","status":"active","text":"Adjusted hazard ratio for cancer incidence with pravastatin use was 0.78, with a 95% confidence interval of 0.18 to 3.46.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c0cbba752a00713606631f7c27497675"},{"public_id":"cl_5a350d0ec042e75fa8f13359ea7d54f7","status":"active","text":"Age and continuous smoking during follow-up were significantly associated with cancer incidence.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5a350d0ec042e75fa8f13359ea7d54f7"},{"public_id":"cl_8433a37f3f0159ec7f6dc9e834327783","status":"active","text":"Five years of pravastatin use did not indicate an increase in overall cancer risk among coronary heart disease patients.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8433a37f3f0159ec7f6dc9e834327783"},{"public_id":"cl_343f9e860f5bd1fe9231526f758ca41c","status":"active","text":"Observed-to-expected analysis found significantly elevated bladder cancer risk in all subjects and in pravastatin users.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_343f9e860f5bd1fe9231526f758ca41c"}],"concepts":[{"public_id":"co_03dafabe2df58591d708f92f7f9800ee","status":"active","name":"cancer incidence","description":"Occurrence of new cancer cases during the five-year follow-up.","types":["outcome"],"aliases":["cancer occurrence"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_03dafabe2df58591d708f92f7f9800ee"},{"public_id":"co_46bb59dc0d6b22594c90b6c88135ec60","status":"active","name":"observed/expected ratio","description":"A comparison of observed cancer counts to expected counts by site.","types":["statistical measure","comparison metric"],"aliases":["O/E ratio"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_46bb59dc0d6b22594c90b6c88135ec60"},{"public_id":"co_5d91b63d208d078f36b088ff4c38dd3a","status":"active","name":"overall cancer risk","description":"The risk of developing any cancer during the follow-up period.","types":["outcome","risk measure"],"aliases":["all cancer incidence"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5d91b63d208d078f36b088ff4c38dd3a"},{"public_id":"co_64aebaae7deb40a2df2f91f7e0a25685","status":"active","name":"bladder cancer","description":"A cancer site analyzed in the observed-to-expected analysis.","types":["cancer site","outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_64aebaae7deb40a2df2f91f7e0a25685"},{"public_id":"co_856964e8560e10f6168effd15f6081f3","status":"active","name":"hazard ratio","description":"A relative risk measure estimated with Cox proportional hazards regression.","types":["statistical measure","effect estimate"],"aliases":["HR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_856964e8560e10f6168effd15f6081f3"},{"public_id":"co_9a25f3392f8bea219b7a4b5beac1e3b9","status":"active","name":"age","description":"Participant age used as a covariate in the risk analysis.","types":["covariate","demographic factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9a25f3392f8bea219b7a4b5beac1e3b9"},{"public_id":"co_a7046ad94272b95d962119660920285d","status":"active","name":"adjusted hazard ratio","description":"A hazard ratio estimated after controlling for selected covariates.","types":["statistical measure","effect estimate"],"aliases":["adjusted HR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a7046ad94272b95d962119660920285d"},{"public_id":"co_b0c987fa85a95a0e1c23a0fc091f6775","status":"active","name":"continuous smoking","description":"Smoking maintained during the follow-up period, assessed as a risk factor.","types":["exposure","covariate"],"aliases":["smoking during the period"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b0c987fa85a95a0e1c23a0fc091f6775"},{"public_id":"co_dda3ac2889fd560b302671747dc96fde","status":"active","name":"Cox’s proportional hazards model","description":"A regression method used to estimate hazard ratios for time-to-event outcomes.","types":["statistical method","survival analysis"],"aliases":["Cox proportional hazards analysis"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dda3ac2889fd560b302671747dc96fde"},{"public_id":"co_ee0d2eefe709f8b3b0f346e9cf24d220","status":"active","name":"pravastatin use","description":"Exposure to the statin pravastatin during the follow-up period.","types":["drug exposure","intervention"],"aliases":["pravastatin therapy","pravastatin treatment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ee0d2eefe709f8b3b0f346e9cf24d220"},{"public_id":"co_f3157ad909f32d61147d7941bc317b91","status":"active","name":"coronary heart disease patients","description":"Patients diagnosed with coronary heart disease who were included in the cohort.","types":["population","patient group"],"aliases":["CHD patients"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f3157ad909f32d61147d7941bc317b91"}],"external_ids":{"DOI":"10.2188/jea.16.201","ArXiv":null,"PubMed":16951539,"PubMedCentral":"7683703","MAG":2073425770,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.jstage.jst.go.jp/article/jea/16/5/16_5_201/_pdf","landing_url":"https://www.semanticscholar.org/paper/5d0cc1a48bc9e7fb46ba1db64448d4ff4924b388","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":636400,"paper_uid":"38db520f-fd99-476d-91fc-f2e9f87d4914","canonical_identity":{"paper_id":636400,"paper_uid":"38db520f-fd99-476d-91fc-f2e9f87d4914","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/24762552"}